

Company, Technology & Opportunity

- Today 60% of all active pharmaceutical ingredients (APIs) with a market value of US\$ 875 BN are large molecules that are administered through injections
- Patients are increasingly asking for needle-free alternatives
- Biotts is a biotech start-up that has developed a unique and proprietary technology that can deliver large molecules through the skin
- A practical example would be the treatment of Diabetes with a weekly insulin patch, replacing daily injections
- The Biotts technology has been tested in clinical studies as safe on humans, it is non-invasive and it can be applied to many other APIs

Market

- Diabetes: 462 million patients in 2017, 643 million by 2030
- Insulin: US\$ 20 billion in 2022, US\$ 23 billion by 2023
- Glucagon-like Peptide-1 Semaglutide: US\$ 18 billion in 2022, US\$ 60 billion by 2030
 - 6 million Diabetes patients in 2022; 25 million by 2030, US\$ 30 billion
 - Rapidly developing sub-market (Obesity) as a weight loss miracle drug; clinically proven up to 20% body weight loss, no side-effects
 - Average consumer spend in the US for weight loss US\$ 1,500 per month, no insurance coverage
 - Obesity sub-market size \$ 30 billion by 2030

Products

- Insulin Patch
 - Proof of Concept in 2023, clinical in 2025, market launch in 2027
 - Partnership with Insulin supplier; jumping board, work horse molecule
 - Strategically important as it will put Biotts and its technology on the pharma map
 - NPV US\$ 10-20 million
- Semaglutide Patch
 - Pre-clinical in 2023, clinical in 2024/2025, market launch in 2030
 - Solo approach to general market
 - Wow-factor: hottest molecule in hot market; revolutionary solution providing superior performance and patient convenience
 - Competitive cost base, competitive advantage increasing in generic space
 - NPV US\$ 2.7 billion
- Exciting and revolutionary products will inspire the industry to build on these successes